ライフサイエンスコーパス: MDR

1 MDR and DCS rates had increased since 2007, but remained

2 MDR and fluoroquinolone-nonsusceptible isolates were mor

3 MDR bacteria isolated from 3.3% and 86.7% of US and Paki

4 MDR gram-negative therapeutic trials are often inefficie

5 MDR S. Typhi was identified in 17% (701/4065) of isolate

6 MDR was not detected at all in other genotypes circulati

7 From 278 MDR-TB/RR-TB index case households, 743 HHCs were enroll

8 tober 2015 to April 2016, 1016 HHCs from 284 MDR-TB cases were enrolled.

9 For example, by 2040, we projected absolute MDR-TB incidence to account for 5% (IQR: 4-9%) of incide

10 t for 2 mo, four mice with late-stage active MDR tuberculosis had a significant decrease in pulmonary

11 e conducted a cross-sectional study of adult MDR-TB cases and their HHCs in 8 countries with high TB

12 ncing to characterise Pseudomonas aeruginosa MDR clinical isolates from a hospital in Thailand.

13 m antibacterial agents with activity against MDR Gram-negative bacteria, including WHO priority patho

14 n have a promising in vitro activity against MDR-E. coli.

15 actam-fosfomycin combination therapy against MDR P. aeruginosa clinical isolate CL232 was further eva

16 clades, which underly 64.2% and 94.0% of all MDR-TB and XDR-TB isolates, respectively.

17 m a previous, population-based study, to all MDR-TB patients reported to the National TB Surveillance

18 Twenty-one patients either had an MDR-TB risk factor and a smear-positive sputum specimen,

19 nfection (from 3.33 to 2.47 per 10,000), and MDR P. aeruginosa infection (from 13.10 to 9.43 per 10,0

20 etect a change in the rates of ESBL, CRE and MDR Pseudomonas aeruginosa following ASP.

21 istant (XDR) E. coli, XDR K. pneumoniae, and MDR A. baumannii were associated with 2-3 times higher m

22 In the case of INH, EMB, PZA and MDR-TB, DeepAMR achieved its best mean sensitivity of 94

23 bapenem-resistant acinetobacter species, and MDR Pseudomonas aeruginosa.

24 important tool for rapid detection of TB and MDR-TB globally.

25 important tool for rapid detection of TB and MDR-TB globally.

26 types involved in community transmission and MDR-TB respectively.

27 d in Mtb following antibiotic-treatment, and MDR-Mtb as mechanisms to circumvent antibiotic effects.

28 h multidrug-resistant gram-negative bacilli (MDR-GNB), accounting for 221 (14%) of all isolates, were

29 genotype isolates appeared more likely to be MDR than other genotypes after controlling for treatment

30 there was a significant relationship between MDR and mortality.

31 0-hospital study of the relationship between MDR pathogens and mortality in India.

32 ch for the treatment of infections caused by MDR bacteria.

33 proportion of latent tuberculosis caused by MDR strains will increase, which will pose serious chall

34 f new tuberculosis cases that were caused by MDR strains.

35 retreatment cases, 12 (16%) were infected by MDR-TB.

36 ate that iron homeostasis can be targeted by MDR-selective compounds for the selective elimination of

37 e percentages of drug-resistant ALDH+ cells, MDR-1/ABCG2 overexpressing cells, and cancer stem-like c

38 pread these mechanisms are among circulating MDR Mtb strains and what impact drug-resistance-conferri

39 for advancing QD nanotherapeutics to combat MDR superbugs.

40 ultidrug resistance (MDR), DCS, and combined MDR/DCS were found in 38.3% (n = 180), 24.5% (n = 115),

41 Compared with conventional MDR-TB treatment, implementing the shorter regimen would

42 ness to take a hypothetical, newly developed MDR TPT if offered.

43 (SNPs), whereas reinfection with a different MDR-TB strain was assumed where the distance was 10 or m

44 Kentucky ST198 displayed MDR and virulent genetic backgrounds.

45 However, donor MDR-GNs were associated with a significant reduction in

46 Though donor MDR-GNs were infrequent in our study, their growing prev

47 2%]) and thus had an opportunity for earlier MDR-TB diagnosis with PSQ on sediment.

48 r surface net heat loss in the north-eastern MDR were the main drivers.

49 itiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are cri

50 idence for the potential uptake of effective MDR TPT when implemented.

51 larvae with DMG prior to injection of either MDR K. pneumoniae or MDR S. Typhimurium led to 40% and 6

52 may represent a novel approach to eliminate MDR cancer cells.

53 39 [2.5%]) were identified as having evolved MDR-TB de novo and 6 as having been reinfected with a di

54 Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were colle

55 phases, and the role of injectable drugs for MDR-TB.

56 ad compounds ranged from 0.125 to 2 mg/L for MDR Gram-negative, excluding Pseudomonas aeruginosa, and

57 aeruginosa, and between 0.03 and 1 mg/L for MDR Gram-positive species.

58 of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and sho

59 endations, an effective all-oral regimen for MDR-TB can be assembled.

60 gy tool for building a treatment regimen for MDR-TB is also provided.Conclusions: New recommendations

61 al injury, and uncover an essential role for MDR efflux pumps in intestinal homeostasis.

62 rently used in children in many settings for MDR-TB treatment, lower doses may approximate current ad

63 ls and thus provides a possible solution for MDR cancers.

64 dults receiving bedaquiline substitution for MDR tuberculosis therapy, plus a matched control group w

65 al dose of linezolid in children treated for MDR-TB.

66 e (9/36 [25%]); or did not have PSQ used for MDR-TB diagnosis (12/38 [32%]) and thus had an opportuni

67 eve particular activities, including forming MDR pumps and cell wall remodeling machineries, to ensur

68 nificant overexpression of GRP78 in all four MDR cell lines compared with the parental cell lines.

69 e elucidated its selective mechanism in four MDR cancer cell lines with one lead candidate (CXL146).

70 An injection-free MDR tuberculosis treatment regimen is now recommended.

71 that could differentiate NTM infection from MDR-TB; however, the most common lesion location in NTM

72 s, 29 (7%) donors grew MDROs and 7 (2%) grew MDR-GNs.

73 Patients were divided into two groups (MDR-TB and XDR-TB) based on two types of drug resistance

74 tive for TB during screening, 11 (2.04%) had MDR-TB, 147 (27.32%) had drug-sensitive TB, and 380 (70.

75 Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), a

76 patients in this case series, 7/14 (50%) had MDR, 4/14 (29%) had pre-extensively-drug-resistant (XDR)

77 ture uncertainty, specific responses to halt MDR-TB transmission should be prioritized.

78 lecting for rifampicin resistance, and hence MDR-TB.

79 amoxicillin, and tetracycline, highlighting MDR P. aeruginosa strains of potential public health con

80 -TB index cases willing to take hypothetical MDR TPT provides important evidence for the potential up

81 HHC willingness to take hypothetical MDR TPT was high (79%) and remained high even with the p

82 Newly identified MDR-related miRNAs (MDRmiRs) enhanced the response to an

83 s also induced IEC delamination, implicating MDR efflux pumps as cellular targets underlying Glafenin

84 ely support GRP78 as the target of CXL146 in MDR treatment.

85 erivatives induced selective cytotoxicity in MDR cancer cells.

86 Furthermore, in MDR cancer cells, danazol reduced STAT3 phosphorylation

87 e conversion (tSCC) and treatment outcome in MDR-tuberculosis patients.

88 lated with unsuccessful treatment outcome in MDR-tuberculosis patients.

89 upregulated the cell cycle inhibitor p21 in MDR cancer cells.

90 CS effect by inhibiting the STAT3 pathway in MDR cancer cells and thus provides a possible solution f

91 ingly, iron depletion was more pronounced in MDR cells due to the Pgp-mediated efflux of NSC297366-ir

92 nd dose-dependently reduced GRP78 protein in MDR cancer cell lines.

93 s, and was common in two highly stable IncI1 MDR plasmids harbouring (bla(CTX-M-1),sul2, tetA) or (bl

94 me, thereby killing the bacterium (including MDR strains).

95 -26%) in Vietnam assuming consistently lower MDR-TB transmission efficiency, versus 15% (IQR: 8-27%)a

96 at targeted GSL modulation could help manage MDR leukemias.

97 We evaluated the accuracy of the BD MAX MDR-TB assay (BD MAX) in South Africa, Uganda, India, an

98 The BD MAX MDR-TB assay had high sensitivity and specificity for de

99 The BD MAX MDR-TB assay had high sensitivity and specificity for de

100 , 35% remained smear positive after a median MDR-TB treatment duration of 8.8 weeks.

101 fective modulators addressing ABCG2-mediated MDR, 23 pyrimidines were synthesized and biologically as

102 reversed ABCB1-, ABCC1-, and ABCG2-mediated MDR, making it one of the three most potent ABC transpor

103 s and reversers of ABC transporters-mediated MDR.

104 Phylogenetic analysis revealed that most MDR/XDR isolates belonged to a subclade of ST298 (design

105 Multidrug (MDR) efflux pumps are ancient and conserved molecular ma

106 hree (2%) S. Paratyphi isolates were MDR; no MDR S. Paratyphi was reported from Bangladesh or Nepal.

107 ority were fluoroquinolone resistant and not MDR.

108 t outcome was observed in 83.5% (132/158) of MDR-tuberculosis patients.

109 At diagnosis, 69% of MDR-TB cases were positive for acid-fast bacilli sputum

110 Danazol induced the arrest of MDR cancer cells at the G2/M phase and caspase-8-related

111 rculosis, 2597 retreatments, and 48 cases of MDR tuberculosis, resulting in a final cohort of 15 501

112 ately 30 years ago was an important cause of MDR-TB in Bamako.

113 Chest X-ray lesion characteristics of MDR-TB show significant correlation among cavities, nodu

114 Clinical and demographic data of MDR-tuberculosis patients in Sweden, including DST resul

115 RRC a suitable method for the development of MDR-based predictors of chemoresistance.

116 bout the relative transmission efficiency of MDR-TB.

117 The emergence of MDR strains is considered a public health threat and ind

118 election, which facilitated the emergence of MDR via two distinct plasmids in communities consisting

119 tly needed to avert the de novo emergence of MDR-TB during treatment.

120 De novo emergence of MDR-TB was assumed where the genomic distance was 5 or f

121 with subsequent multiple emergence events of MDR and XDR-TB particularly involving the Lisboa3 clade.

122 he computed tomography (CT) scan findings of MDR-TB and XDR-TB patients.

123 Our findings indicate that functionality of MDR-1 reveals a critical intersection of metabolite regu

124 evolved stability favoured the generation of MDR cells and thwarted their loss within communities wit

125 ion impaired the malignant glycophenotype of MDR leukemias, which typically overcomes drug resistance

126 In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) ind

127 The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MD

128 gnificant improvement in the inactivation of MDR Pseudomonas aeruginosa and Acinetobacter baumannii (

129 es contribute to an even higher incidence of MDR, given the increased likelihood that a host will alr

130 idly fungicidal against clinical isolates of MDR C. albicans in vitro.

131 cell subpopulation with an elevated level of MDR transport in tumor samples, which makes CRRC a suita

132 liable and revealed long-term maintenance of MDR transport in the dispersed-settled cells obtained fr

133 also effective in vivo with mouse models of MDR tuberculosis infection.

134 y aim was to describe the social networks of MDR tuberculosis cases and controls.

135 osis (p = 0.010), with the best predictor of MDR-TB lesions being the presence of a nodule.

136 The prevalence of MDR invasive NTS (iNTS) was 77.2%, with 15% resistant to

137 rtmental model to project the progression of MDR-TB epidemics in South Africa and Vietnam under alter

138 This 'apparent redundancy' of MDR efflux systems can be understood as a P. aeruginosa

139 ant TB, de novo emergence and reinfection of MDR-TB strains equally contributed to MDR development.

140 We found a subset of MDR inhibitors also induced IEC delamination, implicatin

141 vided on the role of surgery in treatment of MDR-TB and for treatment of contacts exposed to MDR-TB a

142 port use of bedaquiline for the treatment of MDR/XDR TB.

143 to increase HHC confidence in and uptake of MDR TPT.

144 re is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT)

145 r related Beijing isolates that included one MDR-TB isolate.

146 to injection of either MDR K. pneumoniae or MDR S. Typhimurium led to 40% and 60% survival, respecti

147 tive and 41 with isoniazid mono-resistant or MDR TB, were enrolled at one site in South Africa.

148 mice whether infected with drug-sensitive or MDR strains of C. albicans.

149 Current clinical treatments to overcome MDR involve the co-delivery of a Pgp inhibitor and a che

150 actam antibiotics show promise in overcoming MDR P. aeruginosa and are worthy of additional study and

151 In particular, MDR is characterized by increased expression and activit

152 ages of different clones, are phenotypically MDR, and have high resistance gene burdens.

153 The most potent MDR reverser, compound 19, concentration-dependently inc

154 , the application of antibiotics may promote MDR well after their original period of use.

155 rgistic effect with a model deviation ratio (MDR) = 2.1 at 32 mug/L prochloraz and 2.2 at 100 mug/L p

156 n (CAUTI) murine model using UPAB1, a recent MDR urinary isolate.

157 s, and multifactor dimensionality reduction (MDR) analysis.

158 ane activity in the Main Development Region (MDR), a protective barrier of high VWS inhibits hurrican

159 alies (SSTA) in the main development region (MDR, 10-20 degrees N, 20-80 degrees W).

160 tropical cyclone main developmental region (MDR), the El Nino-Southern Oscillation (ENSO), the North

161 cused on finding microRNAs that can regulate MDR proteins by managing corresponding mRNA levels throu

162 Of 586 reported MDR-TB cases, 10% (59) were eligible for the shorter reg

163 equence correspondence to two representative MDR proteins, MGMT (a DNA repair protein) and ABCB1 (an

164 Multiple drug (antibiotic) resistance (MDR) has become a major threat to the treatment of typho

165 very of isolates with multi-drug resistance (MDR) genotypes was lower from McC + CTX than ESBL agar.

166 ted strains exhibited multi-drug resistance (MDR) to amoxicillin, cefotaxime, tetracycline, and genta

167 , and a component of a multidrug resistance (MDR) efflux pump were concluded to be essential for the

168 f-target inhibition of multidrug resistance (MDR) efflux pumps.

169 overcome both BBB and multidrug resistance (MDR) glioma cells while providing site-specific magnetic

170 Multidrug resistance (MDR) in cancer arises from cross-resistance to structura

171 Multidrug resistance (MDR) of pathogens is an ongoing public health crisis exa

172 Multidrug resistance (MDR) represents a global threat to health.

173 in cancer cells confer multidrug resistance (MDR) to therapeutic treatment.

174 a cellular reaction of multidrug resistance (MDR) transport, which was followed by extrusion of a flu

175 orted the frequency of multidrug resistance (MDR)(resistance to ampicillin, cotrimoxazole, and chlora

176 Multidrug resistance (MDR), DCS, and combined MDR/DCS were found in 38.3% (n =

177 suffers seriously from multidrug resistance (MDR), generally caused by innate DNA repair proteins tha

178 transporter conferring multidrug resistance (MDR).

179 f the highest rates of multidrug resistance (MDR).

180 We identified multidrug-resistance (MDR)-associated clade 4.3.1 as the dominant genotype.

181 Numerous PM and multiple disease resistant (MDR) watermelon germplasm lines have been developed by t

182 th 51.9% (28/54) being multi-drug resistant (MDR) and 53.6% of these (15/28) being extensively drug r

183 15% of isolates multi-drug resistant (MDR) to first-line antibiotics and 60% were extensively

184 Multidrug resistant (MDR) bacteria are a global threat with many common infec

185 enetic relationships of multidrug resistant (MDR) bacteria on intensive care unit surfaces from two h

186 gnosis and treatment of multidrug resistant (MDR) bacterial infections.

187 Multidrug resistant (MDR) carbapenemase-producing (CP) Klebsiella pneumoniae,

188 solate and characterize multidrug resistant (MDR) E. coli in raw chicken meat samples collected from

189 Multidrug resistant (MDR) strains of Acinetobacter baumannii present a seriou

190 ic pathogens, including multidrug resistant (MDR) strains of Salmonella Typhimurium and Klebsiella pn

191 0) of NTS isolates were multidrug resistant (MDR; resistant to >=3 antimicrobial classes).

192 ith 51.9% (28/54) being multidrug-resistant (MDR) and 53.6% of these (15/28) being extensively drug-r

193 ced the whole genome of multidrug-resistant (MDR) and extensively drug-resistant (XDR) V. cholerae to

194 Multidrug-resistant (MDR) bacteria that are commonly associated with health c

195 venting and controlling multidrug-resistant (MDR) bacterial infection via eradiation of bacteria and

196 Emergence of multidrug-resistant (MDR) bacterial infections is a major problem in clinical

197 ective toxicity against multidrug-resistant (MDR) cancer.

198 With multidrug-resistant (MDR) Enterobacterales on the rise, a nontoxic antimicrob

199 apenem-resistant and/or multidrug-resistant (MDR) Gram-negative bacteria in clinical settings.

200 nm wavelength) against multidrug-resistant (MDR) Gram-negative bacteria in vitro and in vivo.

201 Treatment options for multidrug-resistant (MDR) gram-negative infection are growing.

202 s with activity against multidrug-resistant (MDR) Gram-negative pathogens as the pipeline of antibiot

203 rt a clonal outbreak of multidrug-resistant (MDR) Klebsiella variicola (sequence type [ST] 771) in a

204 d serves as a source of multidrug-resistant (MDR) mutations.

205 contain drugs to which multidrug-resistant (MDR) Mycobacterium tuberculosis is resistant.

206 current cases of TB are multidrug-resistant (MDR) or rifampicin-resistant.

207 The emergence of multidrug-resistant (MDR) pathogens represents one of the most urgent global

208 LMICs, particularly for multidrug-resistant (MDR) pathogens.

209 lity was restored among multidrug-resistant (MDR) Pseudomonas aeruginosa.

210 Multidrug-resistant (MDR) Salmonella enterica has been deemed a high-priority

211 /mL) and even against a multidrug-resistant (MDR) strain with nearly equal effectiveness.

212 Among 36 patients with multidrug-resistant (MDR) TB who had a sediment specimen submitted for PSQ, m

213 recovered strains were multidrug-resistant (MDR) to penicillins, cephalosporins, and carbapenems, an

214 nce in the treatment of multidrug-resistant (MDR) tuberculosis, but the efficacy and safety of this s

215 to community venues and multidrug-resistant (MDR) tuberculosis.

216 s) and patients who had multidrug-resistant (MDR) tuberculosis.

217 gainst a broad array of multidrug-resistant (MDR), aerobic Gram-negative bacilli.

218 bacterial agent against multidrug-resistant (MDR), biofilm-forming E. coli.

219 accuracy of the BD MAX multidrug-resistant (MDR)-TB assay (BD MAX) in South Africa, Uganda, India, a

220 d two that were largely multidrug-resistant (MDR).

221 oprim-sulfamethoxazole (multidrug-resistant [MDR]).

222 en would have reduced the US annual societal MDR-TB cost burden by 4%, but the cost burden for eligib

223 Our results highlight substantial MDR pathogen burdens in hospital built-environments, pro

224 factors associated with willingness to take MDR TPT, a marginal logistic model was fitted using gene

225 ce on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their ri

226 eing comfortable telling others about taking MDR TPT (aOR, 2.29 [95% CI, 1.29-4.06]).

227 2 [95% CI, 1.23-3.99]), confidence in taking MDR TPT (aOR, 7.16 [95% CI, 3.33-15.42]), and being comf

228 yrazinamide (PZA)], multi-drug resistant TB (MDR-TB) and pan-susceptible TB (PANS-TB: MTB that is sus

229 an increased risk of multidrug-resistant TB (MDR-TB) emerging (8%), compared to drug-sensitive TB (0.

230 -course regimens for multidrug-resistant TB (MDR-TB).

231 emerging threat from multidrug resistant TB (MDR-TB).

232 We found that MDR bacterial infections pose a significant risk to pati

233 We found that MDR is associated with higher UGCG expression and with a

234 Here we show that MDR-1 is present in the oocyte mitochondrial membrane, a

235 ance to front-line treatments and shows that MDR plasmid acquisition in E. cloacae was not indicative

236 w inhibition of GSL biosynthesis affects the MDR phenotype of chronic myeloid leukemias.

237 istically significant difference between the MDR-TB and XDR-TB groups (p > 0.05).

238 was more common in the XDR group than in the MDR group (64.7% and 28.6%, respectively) with a signifi

239 luded fewer and more nodules of 10 mm in the MDR-TB and XDR-TB groups, respectively.

240 Modulation of the MDR phenotype has the potential to increase the efficacy

241 Due to the prevalence of the MDR-TB and extensively drug resistant tuberculosis (XDR-

242 These findings show that the MDR transporter is a "double-edged sword" that can be tu

243 selective cytotoxicity of CXL146 toward the MDR cancer cell lines.

244 R-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of TB disease.

245 An integrated, consensus approach to MDR gram-negative infection trial design is crucial.

246 PSQ, median time from specimen collection to MDR-TB treatment initiation was 12 days vs 51 days when

247 ranscriptional regulators that contribute to MDR phenotype of clinical A. baumannii isolates.

248 ion of MDR-TB strains equally contributed to MDR development.

249 -TB and for treatment of contacts exposed to MDR-TB and treatment of isoniazid-resistant TB.

250 Multidrug resistance transporters (MDRs) are best known for their pathological role in neop

251 ion of CXL146 as a novel therapy in treating MDR cancer cells is warranted.

252 tidrug-resistant Mycobacterium tuberculosis (MDR-TB) accounts for 3.7% of new cases of TB annually wo

253 tidrug-resistant Mycobacterium tuberculosis (MDR-TB) strains making its control difficult.

254 eatment of multidrug-resistant tuberculosis (MDR TB).

255 herapy for multidrug-resistant tuberculosis (MDR TB).

256 r treating multidrug-resistant tuberculosis (MDR TB); however, there is limited data guiding their us

257 ristics of multidrug-resistant tuberculosis (MDR-TB) and non-tuberculous mycobacteria (NTM) infection

258 duals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent dis

259 e assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts (HHCs) to inf

260 istance in multidrug-resistant tuberculosis (MDR-TB) is common and it is not clear how it affects int

261 Multi-drug-resistant tuberculosis (MDR-TB) is simultaneously resistant to isoniazid and rif

262 Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control.

263 -12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to the convention

264 eatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens.

265 r treating multidrug-resistant tuberculosis (MDR-TB); however, there are limited data guiding their u

266 Two MDR Salmonella Typhi isolates from India were found by w

267 The two MDR lineages, one of which resembled S. Typhimurium DT10

268 resistance and growth physiology of the two MDR strains, AYE and AB5075.

269 eligibility for the shorter regimen among US MDR-TB cases that had full drug susceptibility testing (

270 DST use, our analysis found a minority of US MDR-TB patients would have been eligible for the shorter

271 eptible (USVL677-PMS) and resistant (USVL531-MDR) watermelon plants with 10(5) conidia ml(-1) of P. x

272 esignated ST298*) of which 100% (21/21) were MDR and 61.9% (13/21) were XDR.

273 3% of the isolates from broiler chicken were MDR, with the presence of multiple antibiotic resistance

274 n, 16 % (331/2084) of S. Typhi isolates were MDR, and 64% (1319/2074) were XDR.

275 1.09% of layer chicken E. coli isolates were MDR, with 3, 4 or 5 ARGs detected in 36.41%, 14.13%, and

276 = 0.021) and most serotype 6C isolates were MDR.

277 istan, three (2%) S. Paratyphi isolates were MDR; no MDR S. Paratyphi was reported from Bangladesh or

278 Where MDR-TB was diagnosed, WGS was used to determine the geno

279 rred evolutionary history is compatible with MDR- and XDR-TB originating in Portugal in the 70's and

280 e radiographic findings that correlated with MDR-TB were infiltrates (p = 0.010), cavities (p = 0.021

281 cohort study for all patients diagnosed with MDR-TB in Sweden 1992-2014.

282 y, we restricted the analysis to donors with MDR-Gram-negative (GN) organisms.

283 nst Galleria mellonella larvae infected with MDR strains of P. aeruginosa.

284 million) people were latently infected with MDR tuberculosis in 2014-a global prevalence of 0.3% (95

285 ns a therapeutic hope against infection with MDR P. aeruginosa that lack metallo-beta-lactamases.

286 Infections with MDR and extensively drug resistant (XDR) E. coli, XDR K.

287 tive observational study among patients with MDR TB in Georgia receiving a bedaquiline or delamanid-b

288 Among 156 patients with MDR TB, 100 were enrolled and 95 were receiving a bedaqu

289 Among patients with MDR TB, bedaquiline-based regimens were associated with

290 equired to improve outcomes in patients with MDR tuberculosis and pre-XDR or XDR tuberculosis.

291 XDR-TB are similar to those of patients with MDR-TB for cavitary, parenchymal, and non-parenchymal lu

292 ive, observational study among patients with MDR-TB in Georgia who were receiving a bedaquiline- or d

293 Patients with MDR-TB initiated effective treatment 5 weeks earlier whe

294 Among 156 patients with MDR-TB, 100 were enrolled and 95 were receiving a bedaqu

295 Of 157 patients with MDR-TB, 56.1% (n=88) had PZA resistant strains and 49.7%

296 Among patients with MDR-TB, bedaquiline-based regimens were associated with

297 In patients with MDR-TB, gDST PZA resistance was associated with a longer

298 (SCC) and treatment outcome in patients with MDR-TB.

299 istics overlap between XDR-TB and those with MDR-TB.

300 mphenicol), extensive drug resistance (XDR) (MDR plus non-susceptible to fluoroquinolone and any 3rd